Workplace-Sponsored Program to Reduce Obesity
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Images of a Healthy Worksite-Preventing Weight Gain in the Workplace|
- BMI [ Time Frame: Measured at baseline and Year 2 ] [ Designated as safety issue: No ]
- Number of serving of fruits and vegetables [ Time Frame: Measured at baseline and Year 2 ] [ Designated as safety issue: No ]
- Number of steps a day [ Time Frame: Measured at baseline and Year 2 ] [ Designated as safety issue: No ]
|Study Start Date:||September 2004|
|Study Completion Date:||July 2009|
|Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
Worksite intervention for obesity prevention
Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
Other Name: Obesogenic environmentBehavioral: Exercise
Increase routing physical activity, walking routes, stairs intervention, etc.Behavioral: Environment
Cafeteria and vending machine changes and identification of opportunities of physical activity.
No Intervention: 2
Broad, population-based approaches are needed to stop or reverse the rise in obesity prevalence. According to the World Health Organization, obesity prevention can be achieved by promoting a healthy diet and a physically active lifestyle. A partnership with the Eastman Kodak Company has been developed to test a worksite intervention for obesity prevention in Rochester, New York.
The overall goal of this study is to design a comprehensive nutrition and physical activity strategy based on participatory research to promote a healthy lifestyle and to stop the shift of the population body mass index (BMI) curve to the right. Six pairs of worksites will be randomized to either an intervention or control group. Two cross-sectional samples of employees within each worksite will be measured at baseline and at the end of the intervention.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00123513
|United States, New York|
|Eastman Kodak Company|
|Rochester, New York, United States|
|Principal Investigator:||Isabel D. Fernandez, MD, MPH, PhD||University of Rochester|